GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Common Stock

Veracyte (FRA:12V) Common Stock : €0.1 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Common Stock?

Veracyte's quarterly common stock declined from Jun. 2024 (€0.1 Mil) to Sep. 2024 (€0.1 Mil) but then increased from Sep. 2024 (€0.1 Mil) to Dec. 2024 (€0.1 Mil).

Veracyte's annual common stock declined from Dec. 2022 (€0.1 Mil) to Dec. 2023 (€0.1 Mil) but then increased from Dec. 2023 (€0.1 Mil) to Dec. 2024 (€0.1 Mil).


Veracyte Common Stock Historical Data

The historical data trend for Veracyte's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Common Stock Chart

Veracyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.06 0.07 0.07 0.07

Veracyte Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.07 0.07 0.07

Veracyte Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Veracyte Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Veracyte Headlines

No Headlines